据报道,远程医疗公司Hims & Hers Health Inc.(HIMS)今日盘中股价大涨6.98%,引发了市场的广泛关注。公司前三季度业绩优异以及新品规划成为推动股价上涨的主要力量。
财报方面,Hims & Hers前三季度净利润达1亿美元,较去年同期亏损2,479.1万美元实现扭亏为盈,营收同比大增58.9%至9.954亿美元。公司高达80.7%的毛利率为其获取更多利润奠定了坚实基础,体现出强劲的赢利能力。出色的业绩凸显了该公司在远程医疗行业的领先地位和竞争优势。
同时,Hims & Hers计划在2025年推出诺和诺德公司的旧版GLP-1减肥疗法liraglutide的非专利版本,这一产品有望为公司带来新的增长动力。公司表示已确定了核心供应商,正在完成相关测试和验证工作,很快就能推出该新品。
市场对于Hims & Hers的良好财报和新品规划给予了高度认可。分析师预计,该公司强劲的盈利表现和进一步的业务拓展将持续推动其股价上行。投资者看好公司未来,在当日将该股买入力度显著增加,推动股价大涨近7%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.